H1-3 and ovarian cancer: Medrzycki et al. [65] studied the impact of overexpressing histone H1-3 in ovarian cancer cells, which led to reduced growth and altered gene expression by repressing the oncogene H19, proposing H1-3 as both a biomarker and a potential therapeutic target due to its regulatory effects on chromatin structure and gene expression.